Tumors or cancer of the DUODENUM.
Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
Neoplasms containing cyst-like formations or producing mucin or serum.
Tumors or cancer of the SKIN.
Two or more abnormal growths of tissue occurring simultaneously and presumed to be of separate origin. The neoplasms may be histologically the same or different, and may be found in the same or different sites.
Tumors or cancers of the KIDNEY.
Abnormal growths of tissue that follow a previous neoplasm but are not metastases of the latter. The second neoplasm may have the same or different histological type and can occur in the same or different organs as the previous neoplasm but in all cases arises from an independent oncogenic event. The development of the second neoplasm may or may not be related to the treatment for the previous neoplasm since genetic risk or predisposing factors may actually be the cause.
An adenocarcinoma producing mucin in significant amounts. (From Dorland, 27th ed)
Tumors or cancer of the THYROID GLAND.
Conditions which cause proliferation of hemopoietically active tissue or of tissue which has embryonic hemopoietic potential. They all involve dysregulation of multipotent MYELOID PROGENITOR CELLS, most often caused by a mutation in the JAK2 PROTEIN TYROSINE KINASE.
DNA present in neoplastic tissue.
Tumors or cancer of the LUNG.
Tumors or cancer of the PAROTID GLAND.
A benign neoplasm derived from glandular epithelium, in which cystic accumulations of retained secretions are formed. In some instances, considerable portions of the neoplasm, or even the entire mass, may be cystic. (Stedman, 25th ed)
Neoplasms developing from some structure of the connective and subcutaneous tissue. The concept does not refer to neoplasms located in connective or soft tissue.
Neoplasms associated with a proliferation of a single clone of PLASMA CELLS and characterized by the secretion of PARAPROTEINS.
Tumors or cancer of the APPENDIX.
Tumors or cancer of the LIVER.
A multilocular tumor with mucin secreting epithelium. They are most often found in the ovary, but are also found in the pancreas, appendix, and rarely, retroperitoneal and in the urinary bladder. They are considered to have low-grade malignant potential.
Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.
Tumors or cancer of the ENDOCRINE GLANDS.
Tumors or cancer of the GASTROINTESTINAL TRACT, from the MOUTH to the ANAL CANAL.
Carcinoma that arises from the PANCREATIC DUCTS. It accounts for the majority of cancers derived from the PANCREAS.
Experimentally induced new abnormal growth of TISSUES in animals to provide models for studying human neoplasms.
Neoplasms composed of vascular tissue. This concept does not refer to neoplasms located in blood vessels.
Tumors or cancer of the EYE.
Histochemical localization of immunoreactive substances using labeled antibodies as reagents.
Tumors or cancer of the NOSE.
Tumors or cancer of the SALIVARY GLANDS.
Tumors, cancer or other neoplasms produced by exposure to ionizing or non-ionizing radiation.
An adenocarcinoma containing finger-like processes of vascular connective tissue covered by neoplastic epithelium, projecting into cysts or the cavity of glands or follicles. It occurs most frequently in the ovary and thyroid gland. (Stedman, 25th ed)
A malignant neoplasm characterized by the formation of numerous, irregular, finger-like projections of fibrous stroma that is covered with a surface layer of neoplastic epithelial cells. (Stedman, 25th ed)
Tumors or cancer of the TESTIS. Germ cell tumors (GERMINOMA) of the testis constitute 95% of all testicular neoplasms.
Neoplasms composed of muscle tissue: skeletal, cardiac, or smooth. The concept does not refer to neoplasms located in muscles.
Neoplasms composed of glandular tissue, an aggregation of epithelial cells that elaborate secretions, and of any type of epithelium itself. The concept does not refer to neoplasms located in the various glands or in epithelial tissue.
A malignant cystic or semisolid tumor most often occurring in the ovary. Rarely, one is solid. This tumor may develop from a mucinous cystadenoma, or it may be malignant at the onset. The cysts are lined with tall columnar epithelial cells; in others, the epithelium consists of many layers of cells that have lost normal structure entirely. In the more undifferentiated tumors, one may see sheets and nests of tumor cells that have very little resemblance to the parent structure. (Hughes, Obstetric-Gynecologic Terminology, 1972, p184)
A benign epithelial tumor with a glandular organization.
Neoplasms of whatever cell type or origin, occurring in the extraskeletal connective tissue framework of the body including the organs of locomotion and their various component structures, such as nerves, blood vessels, lymphatics, etc.
Neoplasms located in the blood and blood-forming tissue (the bone marrow and lymphatic tissue). The commonest forms are the various types of LEUKEMIA, of LYMPHOMA, and of the progressive, life-threatening forms of the MYELODYSPLASTIC SYNDROMES.
Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm.
Tumors or cancer of the UTERUS.
Tumors or cancer of the INTESTINES.
Neoplasms composed of sebaceous or sweat gland tissue or tissue of other skin appendages. The concept does not refer to neoplasms located in the sebaceous or sweat glands or in the other skin appendages.
Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.
Neoplasms located in the vasculature system, such as ARTERIES and VEINS. They are differentiated from neoplasms of vascular tissue (NEOPLASMS, VASCULAR TISSUE), such as ANGIOFIBROMA or HEMANGIOMA.
Sweat gland neoplasms are abnormal growths that can be benign or malignant, originating from the sweat glands (eccrine or apocrine) and found anywhere on the skin surface.
A general term for various neoplastic diseases of the lymphoid tissue.
Tumors or cancer located in bone tissue or specific BONES.
Tumors or cancer of the PALATE, including those of the hard palate, soft palate and UVULA.

Administration of an unconjugated bile acid increases duodenal tumors in a murine model of familial adenomatous polyposis. (1/371)

Intestinal carcinogenesis involves the successive accumulation of multiple genetic defects until cellular transformation to an invasive phenotype occurs. This process is modulated by many epigenetic factors. Unconjugated bile acids are tumor promoters whose presence in intestinal tissues is regulated by dietary factors. We studied the role of the unconjugated bile acid, chenodeoxycholate, in an animal model of familial adenomatous polyposis. Mice susceptible to intestinal tumors as a result of a germline mutation in Apc (Min/+ mice) were given a 10 week dietary treatment with 0.5% chenodeoxycholate. Following this, the mice were examined to determine tumor number, enterocyte proliferation, apoptosis and beta-catenin expression. Intestinal tissue prostaglandin E2 (PGE2) levels were also assessed. Administration of chenodeoxycholate in the diet increased duodenal tumor number in Min/+ mice. Promotion of duodenal tumor formation was accompanied by increased beta-catenin expression in duodenal cells, as well as increased PGE2 in duodenal tissue. These data suggest that unconjugated bile acids contribute to periampullary tumor formation in the setting of an Apc mutation.  (+info)

Elevated reticulocyte count--a clue to the diagnosis of haemolytic-uraemic syndrome (HUS) associated with gemcitabine therapy for metastatic duodenal papillary carcinoma: a case report. (2/371)

In adults, the haemolytic-uraemic syndrome (HUS) is associated with probable causative factors in the minority of all cases. Cytotoxic drugs are one of these potential causative agents. Although metastatic cancer by itself is a recognized risk-factor for the development of HUS, therapy with mitomycin-C, with cis-platinum, and with bleomycin carries a significant, albeit extremely small, risk for the development of HUS, compared with all other cytotoxic drugs. Gemcitabine is a novel cytotoxic drug with promising activity against pancreatic adenocarcinoma. We are reporting on one patient with metastatic duodenal papillary carcinoma developing HUS while on weekly gemcitabine therapy. The presenting features in this patient were non-cardiac pulmonary oedema, renal failure, thrombocytopenia and haemolytic anaemia. The diagnosis of HUS was made on the day of admission of the patient to this institution. Upon aggressive therapy, including one single haemodialysis and five plasmaphereses, the patient recovered uneventfully, with modestly elevated creatinine-values as a remnant of the acute illness. Re-exposure to gemcitabine 6 months after the episode of HUS instituted for progressive carcinoma, thus far has not caused another episode of HUS.  (+info)

Descriptive epidemiology of small intestinal malignancies: the German Cancer Registry experience. (3/371)

In the first population-based analysis of certain epidemiologic features of primary malignancies of the small intestine in Germany, we used data from the Saarland Cancer Registry (1982-1993) and from the former National Cancer Registry of the German Democratic Republic (1976-1989). The age-standardized incidence rates for ages 0-74 years is 3.3-6.2 per million per year. The average incidence rates of the federal state Saarland are for men about 1.3 times and for women about 1.4 times the rate of the former German Democratic Republic. After the age of 30 years, the incidence rates increased with increasing age. Incidence rates for carcinoids levelled off after the age of 54 years. Rates for men were 35-40% higher than for women after adjusting for age. The risk for carcinomas, malignant carcinoids and malignant lymphoma were higher for men than for women.  (+info)

Surgery to cure the Zollinger-Ellison syndrome. (4/371)

BACKGROUND AND METHODS: The role of surgery in patients with the Zollinger-Ellison syndrome is controversial. To determine the efficacy of surgery in patients with this syndrome, we followed 151 consecutive patients who underwent laparotomy between 1981 and 1998. Of these patients, 123 had sporadic gastrinomas and 28 had multiple endocrine neoplasia type 1 with an imaged tumor of at least 3 cm in diameter. Tumor-localization studies and functional localization studies were performed routinely. All patients underwent surgery according to a similar operative protocol, and all patients who had surgery after 1986 underwent duodenotomy. RESULTS: The 151 patients underwent 180 exploratory operations. The mean (+/-SD) follow-up after the first operation was 8+/-4 years. Gastrinomas were found in 141 of the patients (93 percent), including all of the last 81 patients to undergo surgery. The tumors were located in the duodenum in 74 patients (49 percent) and in the pancreas in 36 patients (24 percent); however, primary tumors were found in lymph nodes in 17 patients (11 percent) and in another location in 13 patients (9 percent). The primary location was unknown in 24 patients (16 percent). Among the patients with sporadic gastrinomas, 34 percent were free of disease at 10 years, as compared with none of the patients with multiple endocrine neoplasia type 1. The overall 10-year survival rate was 94 percent. CONCLUSIONS: All patients with the Zollinger-Ellison syndrome who do not have multiple endocrine neoplasia type 1 or metastatic disease should be offered surgical exploration for possible cure.  (+info)

Is prophylactic gastrojejunostomy indicated for unresectable periampullary cancer? A prospective randomized trial. (5/371)

OBJECTIVE: This prospective, randomized, single-institution trial was designed to evaluate the role of prophylactic gastrojejunostomy in patients found at exploratory laparotomy to have unresectable periampullary carcinoma. SUMMARY BACKGROUND DATA: Between 25% and 75% of patients with periampullary cancer who undergo exploratory surgery with intent to perform a pancreaticoduodenectomy are found to have unresectable disease. Most will undergo a biliary-enteric bypass. Whether or not to perform a prophylactic gastrojejunostomy remains unresolved. Retrospective reviews of surgical series and prospective randomized trials of endoscopic palliation have demonstrated that late gastric outlet obstruction, requiring a gastrojejunostomy, develops in 10% to 20% of patients with unresectable periampullary cancer. METHODS: Between May 1994 and October 1998, 194 patients with a periampullary malignancy underwent exploratory surgery with the purpose of performing a pancreaticoduodenectomy and were found to have unresectable disease. On the basis of preoperative symptoms, radiologic studies, or surgical findings, the surgeon determined that gastric outlet obstruction was a significant risk in 107 and performed a gastrojejunostomy. The remaining 87 patients were thought by the surgeon not to be at significant risk for duodenal obstruction and were randomized to receive either a prophylactic retrocolic gastrojejunostomy or no gastrojejunostomy. Short- and long-term outcomes were determined in all patients. RESULTS: Of the 87 patients randomized, 44 patients underwent a retrocolic gastrojejunostomy and 43 did not undergo a gastric bypass. The two groups were similar with respect to age, gender, procedure performed (excluding gastrojejunostomy), and surgical findings. There were no postoperative deaths in either group, and the postoperative morbidity rates were comparable (gastrojejunostomy 32%, no gastrojejunostomy 33%). The postoperative length of stay was 8.5+/-0.5 days for the gastrojejunostomy group and 8.0+/-0.5 days for the no gastrojejunostomy group. Mean survival among those who received a prophylactic gastrojejunostomy was 8.3 months, and during that interval gastric outlet obstruction developed in none of the 44 patients. Mean survival among those who did not have a prophylactic gastrojejunostomy was 8.3 months. In 8 of those 43 patients (19%), late gastric outlet obstruction developed, requiring therapeutic intervention (gastrojejunostomy 7 patients, endoscopic duodenal stent 1 patient; p < 0.01). The median time between initial exploration and therapeutic intervention was 2 months. CONCLUSION: The results from this prospective, randomized trial demonstrate that prophylactic gastrojejunostomy significantly decreases the incidence of late gastric outlet obstruction. The performance of a prophylactic retrocolic gastrojejunostomy at the initial surgical procedure does not increase the incidence of postoperative complications or extend the length of stay. A retrocolic gastrojejunostomy should be performed routinely when a patient is undergoing surgical palliation for unresectable periampullary carcinoma.  (+info)

Gastric and duodenal polyps in Smad4 (Dpc4) knockout mice. (6/371)

The SMAD4 (DPC4) gene was initially isolated as a candidate tumor suppressor from the convergent site of homozygous deletions on 18q in a panel of pancreatic carcinoma cell lines. It encodes a common cytoplasmic signaling molecule shared by the transforming growth factor-beta, activin, and bone morphogenic pathways. We recently inactivated its mouse homologue Smad4 and demonstrated its role in the malignant progression of benign adenomas to invasive adenocarcinomas by analyzing mice with Apc and Smad4 compound mutations. Although simple Smad4 homozygotes were embryonically lethal, the heterozygotes were fertile and appeared normal up to the age of 1 year. Upon further investigation, however, they have developed inflammatory polyps in the glandular stomach and duodenum. By PCR genotyping and immunohistochemical staining, the wild-type Smad4 allele has been lost in the polyp epithelial cells, ie., loss of heterozygosity. On the other hand, we have not found any mutations in such genes as K-Ras, H-Ras, N-Ras, p53, or PTEN. Histologically, the polyps are similar to human juvenile polyps showing moderate stromal cell proliferation and infiltrations by eosinophils and plasma cells. In addition, foci of adenocarcinoma with signet ring cells are also found. These results are consistent with a recent report that germ-line SMAD4 mutations are found in a subset of familial juvenile polyposis.  (+info)

Primary duodenal MALT lymphoma. (7/371)

Primary duodenal MALT lymphoma (MALToma) is a very rare neoplasm arising from the mucosa-associated lymphoid tissue of the duodenum. We report a 55-year-old woman with MALToma located in the descending duodenum and accompanying Helicobacter pylori infection of the stomach. We performed operative resection due to involvement of the papilla of Vater and submucosal tumor infiltration. Despite wide mucosal spreading, postoperative examination revealed only a small amount of MALToma cells infiltrating into the submucosa. No invasion into the adjacent structure or metastasis to regional lymph nodes was confirmed, suggesting the disease could have been controlled by eradication of Helicobacter pylori.  (+info)

Establishment and analysis of biological characteristics of a human duodenal carcinoma cell line, WDC-1. (8/371)

BACKGROUND: Duodenal carcinoma is very rare and its culture cell lines have rarely been established. METHODS: Tumor cells separated from a surgically resected primary tumor of duodenal carcinoma were put into culture. The patient was an 81-year-old female and had metastatic lymph nodes. We investigated the biological characteristics of the culture cells including in vitro cell kinetics, karyotype, expression of tumor markers and integrins and tumorigenicity and histology in nude mice. RESULTS: A new cell line, designated WDC-1, was established. This duodenal carcinoma cell line proliferated in a monolayered sheet with a doubling time of 50 h. The histological findings of the xenograft in nude mice were similar to those of the primary tumor. WDC-1 cells produced carcinoembryonic antigen and expressed 1 integrin and very late antigen (VLA)-4d in vitro. CONCLUSIONS: A duodenal carcinoma cell line was established, which is rare and may contribute to progress in understanding the biological features of duodenal cancer.  (+info)

Duodenal neoplasms refer to abnormal growths in the duodenum, which is the first part of the small intestine that receives digestive secretions from the pancreas and bile duct. These growths can be benign or malignant (cancerous).

Benign neoplasms include adenomas, leiomyomas, lipomas, and hamartomas. They are usually slow-growing and do not spread to other parts of the body. However, they may cause symptoms such as abdominal pain, bleeding, or obstruction of the intestine.

Malignant neoplasms include adenocarcinomas, neuroendocrine tumors (carcinoids), lymphomas, and sarcomas. They are more aggressive and can invade surrounding tissues and spread to other parts of the body. Symptoms may include abdominal pain, weight loss, jaundice, anemia, or bowel obstruction.

The diagnosis of duodenal neoplasms is usually made through imaging tests such as CT scans, MRI, or endoscopy with biopsy. Treatment depends on the type and stage of the tumor and may include surgery, chemotherapy, radiation therapy, or a combination of these modalities.

Pancreatic neoplasms refer to abnormal growths in the pancreas that can be benign or malignant. The pancreas is a gland located behind the stomach that produces hormones and digestive enzymes. Pancreatic neoplasms can interfere with the normal functioning of the pancreas, leading to various health complications.

Benign pancreatic neoplasms are non-cancerous growths that do not spread to other parts of the body. They are usually removed through surgery to prevent any potential complications, such as blocking the bile duct or causing pain.

Malignant pancreatic neoplasms, also known as pancreatic cancer, are cancerous growths that can invade and destroy surrounding tissues and organs. They can also spread (metastasize) to other parts of the body, such as the liver, lungs, or bones. Pancreatic cancer is often aggressive and difficult to treat, with a poor prognosis.

There are several types of pancreatic neoplasms, including adenocarcinomas, neuroendocrine tumors, solid pseudopapillary neoplasms, and cystic neoplasms. The specific type of neoplasm is determined through various diagnostic tests, such as imaging studies, biopsies, and blood tests. Treatment options depend on the type, stage, and location of the neoplasm, as well as the patient's overall health and preferences.

Neoplasms are abnormal growths of cells or tissues in the body that serve no physiological function. They can be benign (non-cancerous) or malignant (cancerous). Benign neoplasms are typically slow growing and do not spread to other parts of the body, while malignant neoplasms are aggressive, invasive, and can metastasize to distant sites.

Neoplasms occur when there is a dysregulation in the normal process of cell division and differentiation, leading to uncontrolled growth and accumulation of cells. This can result from genetic mutations or other factors such as viral infections, environmental exposures, or hormonal imbalances.

Neoplasms can develop in any organ or tissue of the body and can cause various symptoms depending on their size, location, and type. Treatment options for neoplasms include surgery, radiation therapy, chemotherapy, immunotherapy, and targeted therapy, among others.

Neoplasms: Neoplasms refer to abnormal growths of tissue that can be benign (non-cancerous) or malignant (cancerous). They occur when the normal control mechanisms that regulate cell growth and division are disrupted, leading to uncontrolled cell proliferation.

Cystic Neoplasms: Cystic neoplasms are tumors that contain fluid-filled sacs or cysts. These tumors can be benign or malignant and can occur in various organs of the body, including the pancreas, ovary, and liver.

Mucinous Neoplasms: Mucinous neoplasms are a type of cystic neoplasm that is characterized by the production of mucin, a gel-like substance produced by certain types of cells. These tumors can occur in various organs, including the ovary, pancreas, and colon. Mucinous neoplasms can be benign or malignant, and malignant forms are often aggressive and have a poor prognosis.

Serous Neoplasms: Serous neoplasms are another type of cystic neoplasm that is characterized by the production of serous fluid, which is a thin, watery fluid. These tumors commonly occur in the ovary and can be benign or malignant. Malignant serous neoplasms are often aggressive and have a poor prognosis.

In summary, neoplasms refer to abnormal tissue growths that can be benign or malignant. Cystic neoplasms contain fluid-filled sacs and can occur in various organs of the body. Mucinous neoplasms produce a gel-like substance called mucin and can also occur in various organs, while serous neoplasms produce thin, watery fluid and commonly occur in the ovary. Both mucinous and serous neoplasms can be benign or malignant, with malignant forms often being aggressive and having a poor prognosis.

Skin neoplasms refer to abnormal growths or tumors in the skin that can be benign (non-cancerous) or malignant (cancerous). They result from uncontrolled multiplication of skin cells, which can form various types of lesions. These growths may appear as lumps, bumps, sores, patches, or discolored areas on the skin.

Benign skin neoplasms include conditions such as moles, warts, and seborrheic keratoses, while malignant skin neoplasms are primarily classified into melanoma, squamous cell carcinoma, and basal cell carcinoma. These three types of cancerous skin growths are collectively known as non-melanoma skin cancers (NMSCs). Melanoma is the most aggressive and dangerous form of skin cancer, while NMSCs tend to be less invasive but more common.

It's essential to monitor any changes in existing skin lesions or the appearance of new growths and consult a healthcare professional for proper evaluation and treatment if needed.

Multiple primary neoplasms refer to the occurrence of more than one primary malignant tumor in an individual, where each tumor is unrelated to the other and originates from separate cells or organs. This differs from metastatic cancer, where a single malignancy spreads to multiple sites in the body. Multiple primary neoplasms can be synchronous (occurring at the same time) or metachronous (occurring at different times). The risk of developing multiple primary neoplasms increases with age and is associated with certain genetic predispositions, environmental factors, and lifestyle choices such as smoking and alcohol consumption.

Kidney neoplasms refer to abnormal growths or tumors in the kidney tissues that can be benign (non-cancerous) or malignant (cancerous). These growths can originate from various types of kidney cells, including the renal tubules, glomeruli, and the renal pelvis.

Malignant kidney neoplasms are also known as kidney cancers, with renal cell carcinoma being the most common type. Benign kidney neoplasms include renal adenomas, oncocytomas, and angiomyolipomas. While benign neoplasms are generally not life-threatening, they can still cause problems if they grow large enough to compromise kidney function or if they undergo malignant transformation.

Early detection and appropriate management of kidney neoplasms are crucial for improving patient outcomes and overall prognosis. Regular medical check-ups, imaging studies, and urinalysis can help in the early identification of these growths, allowing for timely intervention and treatment.

A "second primary neoplasm" is a distinct, new cancer or malignancy that develops in a person who has already had a previous cancer. It is not a recurrence or metastasis of the original tumor, but rather an independent cancer that arises in a different location or organ system. The development of second primary neoplasms can be influenced by various factors such as genetic predisposition, environmental exposures, and previous treatments like chemotherapy or radiation therapy.

It is important to note that the definition of "second primary neoplasm" may vary slightly depending on the specific source or context. In general medical usage, it refers to a new, separate cancer; however, in some research or clinical settings, there might be more precise criteria for defining and diagnosing second primary neoplasms.

Adenocarcinoma, mucinous is a type of cancer that begins in the glandular cells that line certain organs and produce mucin, a substance that lubricates and protects tissues. This type of cancer is characterized by the presence of abundant pools of mucin within the tumor. It typically develops in organs such as the colon, rectum, lungs, pancreas, and ovaries.

Mucinous adenocarcinomas tend to have a distinct appearance under the microscope, with large pools of mucin pushing aside the cancer cells. They may also have a different clinical behavior compared to other types of adenocarcinomas, such as being more aggressive or having a worse prognosis in some cases.

It is important to note that while a diagnosis of adenocarcinoma, mucinous can be serious, the prognosis and treatment options may vary depending on several factors, including the location of the cancer, the stage at which it was diagnosed, and the individual's overall health.

Thyroid neoplasms refer to abnormal growths or tumors in the thyroid gland, which can be benign (non-cancerous) or malignant (cancerous). These growths can vary in size and may cause a noticeable lump or nodule in the neck. Thyroid neoplasms can also affect the function of the thyroid gland, leading to hormonal imbalances and related symptoms. The exact causes of thyroid neoplasms are not fully understood, but risk factors include radiation exposure, family history, and certain genetic conditions. It is important to note that most thyroid nodules are benign, but a proper medical evaluation is necessary to determine the nature of the growth and develop an appropriate treatment plan.

Myeloproliferative disorders (MPDs) are a group of rare, chronic blood cancers that originate from the abnormal proliferation or growth of one or more types of blood-forming cells in the bone marrow. These disorders result in an overproduction of mature but dysfunctional blood cells, which can lead to serious complications such as blood clots, bleeding, and organ damage.

There are several subtypes of MPDs, including:

1. Chronic Myeloid Leukemia (CML): A disorder characterized by the overproduction of mature granulocytes (a type of white blood cell) in the bone marrow, leading to an increased number of these cells in the blood. CML is caused by a genetic mutation that results in the formation of the BCR-ABL fusion protein, which drives uncontrolled cell growth and division.
2. Polycythemia Vera (PV): A disorder characterized by the overproduction of all three types of blood cells - red blood cells, white blood cells, and platelets - in the bone marrow. This can lead to an increased risk of blood clots, bleeding, and enlargement of the spleen.
3. Essential Thrombocythemia (ET): A disorder characterized by the overproduction of platelets in the bone marrow, leading to an increased risk of blood clots and bleeding.
4. Primary Myelofibrosis (PMF): A disorder characterized by the replacement of normal bone marrow tissue with scar tissue, leading to impaired blood cell production and anemia, enlargement of the spleen, and increased risk of infections and bleeding.
5. Chronic Neutrophilic Leukemia (CNL): A rare disorder characterized by the overproduction of neutrophils (a type of white blood cell) in the bone marrow, leading to an increased number of these cells in the blood. CNL can lead to an increased risk of infections and organ damage.

MPDs are typically treated with a combination of therapies, including chemotherapy, targeted therapy, immunotherapy, and stem cell transplantation. The choice of treatment depends on several factors, including the subtype of MPD, the patient's age and overall health, and the presence of any comorbidities.

The term "DNA, neoplasm" is not a standard medical term or concept. DNA refers to deoxyribonucleic acid, which is the genetic material present in the cells of living organisms. A neoplasm, on the other hand, is a tumor or growth of abnormal tissue that can be benign (non-cancerous) or malignant (cancerous).

In some contexts, "DNA, neoplasm" may refer to genetic alterations found in cancer cells. These genetic changes can include mutations, amplifications, deletions, or rearrangements of DNA sequences that contribute to the development and progression of cancer. Identifying these genetic abnormalities can help doctors diagnose and treat certain types of cancer more effectively.

However, it's important to note that "DNA, neoplasm" is not a term that would typically be used in medical reports or research papers without further clarification. If you have any specific questions about DNA changes in cancer cells or neoplasms, I would recommend consulting with a healthcare professional or conducting further research on the topic.

Lung neoplasms refer to abnormal growths or tumors in the lung tissue. These tumors can be benign (non-cancerous) or malignant (cancerous). Malignant lung neoplasms are further classified into two main types: small cell lung carcinoma and non-small cell lung carcinoma. Lung neoplasms can cause symptoms such as cough, chest pain, shortness of breath, and weight loss. They are often caused by smoking or exposure to secondhand smoke, but can also occur due to genetic factors, radiation exposure, and other environmental carcinogens. Early detection and treatment of lung neoplasms is crucial for improving outcomes and survival rates.

Parotid neoplasms refer to abnormal growths or tumors in the parotid gland, which is the largest of the salivary glands and is located in front of the ear and extends down the neck. These neoplasms can be benign (non-cancerous) or malignant (cancerous).

Benign parotid neoplasms are typically slow-growing, painless masses that may cause facial asymmetry or difficulty in chewing or swallowing if they become large enough to compress surrounding structures. The most common type of benign parotid tumor is a pleomorphic adenoma.

Malignant parotid neoplasms, on the other hand, are more aggressive and can invade nearby tissues and spread to other parts of the body. They may present as rapidly growing masses that are firm or fixed to surrounding structures. Common types of malignant parotid tumors include mucoepidermoid carcinoma, adenoid cystic carcinoma, and squamous cell carcinoma.

The diagnosis of parotid neoplasms typically involves a thorough clinical evaluation, imaging studies such as CT or MRI scans, and fine-needle aspiration biopsy (FNAB) to determine the nature of the tumor. Treatment options depend on the type, size, and location of the neoplasm but may include surgical excision, radiation therapy, and chemotherapy.

Cystadenoma is a type of benign tumor (not cancerous), which arises from glandular epithelial cells and is covered by a thin layer of connective tissue. These tumors can develop in various locations within the body, including the ovaries, pancreas, and other organs that contain glands.

There are two main types of cystadenomas: serous and mucinous. Serous cystadenomas are filled with a clear or watery fluid, while mucinous cystadenomas contain a thick, gelatinous material. Although they are generally not harmful, these tumors can grow quite large and cause discomfort or other symptoms due to their size or location. In some cases, cystadenomas may undergo malignant transformation and develop into cancerous tumors, known as cystadenocarcinomas. Regular medical follow-up and monitoring are essential for individuals diagnosed with cystadenomas to ensure early detection and treatment of any potential complications.

Neoplasms of connective and soft tissue are abnormal growths or tumors that develop in the body's supportive tissues, such as cartilage, tendons, ligaments, fascia, and fat. These neoplasms can be benign (non-cancerous) or malignant (cancerous).

Benign connective and soft tissue neoplasms include:
- Lipomas: slow-growing, fatty tumors that develop under the skin.
- Fibromas: firm, benign tumors that develop in connective tissue such as tendons or ligaments.
- Nevi (plural of nevus): benign growths made up of cells called melanocytes, which produce pigment.

Malignant connective and soft tissue neoplasms include:
- Sarcomas: a type of cancer that develops in the body's supportive tissues such as muscle, bone, fat, cartilage, or blood vessels. There are many different types of sarcomas, including liposarcoma (fatty tissue), rhabdomyosarcoma (muscle), and osteosarcoma (bone).
- Desmoid tumors: a rare type of benign tumor that can become aggressive and invade surrounding tissues. While not considered cancerous, desmoid tumors can cause significant morbidity due to their tendency to grow and infiltrate nearby structures.

Connective and soft tissue neoplasms can present with various symptoms depending on their location and size. Treatment options include surgery, radiation therapy, chemotherapy, or a combination of these modalities. Regular follow-up care is essential to monitor for recurrence or metastasis (spread) of the tumor.

Plasma cell neoplasms are a type of cancer that originates from plasma cells, which are a type of white blood cell found in the bone marrow. These cells are responsible for producing antibodies to help fight off infections. When plasma cells become cancerous and multiply out of control, they can form a tumor called a plasmacytoma.

There are two main types of plasma cell neoplasms: solitary plasmacytoma and multiple myeloma. Solitary plasmacytoma is a localized tumor that typically forms in the bone, while multiple myeloma is a systemic disease that affects multiple bones and can cause a variety of symptoms such as bone pain, fatigue, and anemia.

Plasma cell neoplasms are diagnosed through a combination of tests, including blood tests, imaging studies, and bone marrow biopsy. Treatment options depend on the stage and extent of the disease, but may include radiation therapy, chemotherapy, and stem cell transplantation.

Appendiceal neoplasms refer to various types of tumors that can develop in the appendix, a small tube-like structure attached to the large intestine. These neoplasms can be benign or malignant and can include:

1. Adenomas: These are benign tumors that arise from the glandular cells lining the appendix. They are usually slow-growing and may not cause any symptoms.
2. Carcinoids: These are neuroendocrine tumors that arise from the hormone-producing cells in the appendix. They are typically small and slow-growing, but some can be aggressive and spread to other parts of the body.
3. Mucinous neoplasms: These are tumors that produce mucin, a slippery substance that can cause the appendix to become distended and filled with mucus. They can be low-grade (less aggressive) or high-grade (more aggressive) and may spread to other parts of the abdomen.
4. Adenocarcinomas: These are malignant tumors that arise from the glandular cells lining the appendix. They are relatively rare but can be aggressive and spread to other parts of the body.
5. Pseudomyxoma peritonei: This is a condition in which mucin produced by an appendiceal neoplasm leaks into the abdominal cavity, causing a jelly-like accumulation of fluid and tissue. It can be caused by both benign and malignant tumors.

Treatment for appendiceal neoplasms depends on the type and stage of the tumor, as well as the patient's overall health. Treatment options may include surgery, chemotherapy, or radiation therapy.

Liver neoplasms refer to abnormal growths in the liver that can be benign or malignant. Benign liver neoplasms are non-cancerous tumors that do not spread to other parts of the body, while malignant liver neoplasms are cancerous tumors that can invade and destroy surrounding tissue and spread to other organs.

Liver neoplasms can be primary, meaning they originate in the liver, or secondary, meaning they have metastasized (spread) to the liver from another part of the body. Primary liver neoplasms can be further classified into different types based on their cell of origin and behavior, including hepatocellular carcinoma, cholangiocarcinoma, and hepatic hemangioma.

The diagnosis of liver neoplasms typically involves a combination of imaging studies, such as ultrasound, CT scan, or MRI, and biopsy to confirm the type and stage of the tumor. Treatment options depend on the type and extent of the neoplasm and may include surgery, radiation therapy, chemotherapy, or liver transplantation.

Mucinous cystadenoma is a type of benign tumor that arises from the epithelial cells lining the mucous membranes of the body. It is most commonly found in the ovary, but can also occur in other locations such as the pancreas or appendix.

Mucinous cystadenomas are characterized by the production of large amounts of mucin, a slippery, gel-like substance that accumulates inside the tumor and causes it to grow into a cystic mass. These tumors can vary in size, ranging from a few centimeters to over 20 centimeters in diameter.

While mucinous cystadenomas are generally benign, they have the potential to become cancerous (mucinous cystadenocarcinoma) if left untreated. Symptoms of mucinous cystadenoma may include abdominal pain or swelling, bloating, and changes in bowel movements or urinary habits. Treatment typically involves surgical removal of the tumor.

Ovarian neoplasms refer to abnormal growths or tumors in the ovary, which can be benign (non-cancerous) or malignant (cancerous). These growths can originate from various cell types within the ovary, including epithelial cells, germ cells, and stromal cells. Ovarian neoplasms are often classified based on their cell type of origin, histological features, and potential for invasive or metastatic behavior.

Epithelial ovarian neoplasms are the most common type and can be further categorized into several subtypes, such as serous, mucinous, endometrioid, clear cell, and Brenner tumors. Some of these epithelial tumors have a higher risk of becoming malignant and spreading to other parts of the body.

Germ cell ovarian neoplasms arise from the cells that give rise to eggs (oocytes) and can include teratomas, dysgerminomas, yolk sac tumors, and embryonal carcinomas. Stromal ovarian neoplasms develop from the connective tissue cells supporting the ovary and can include granulosa cell tumors, thecomas, and fibromas.

It is essential to diagnose and treat ovarian neoplasms promptly, as some malignant forms can be aggressive and potentially life-threatening if not managed appropriately. Regular gynecological exams, imaging studies, and tumor marker tests are often used for early detection and monitoring of ovarian neoplasms. Treatment options may include surgery, chemotherapy, or radiation therapy, depending on the type, stage, and patient's overall health condition.

Endocrine gland neoplasms refer to abnormal growths (tumors) that develop in the endocrine glands. These glands are responsible for producing hormones, which are chemical messengers that regulate various functions and processes in the body. Neoplasms can be benign or malignant (cancerous). Benign neoplasms tend to grow slowly and do not spread to other parts of the body. Malignant neoplasms, on the other hand, can invade nearby tissues and organs and may also metastasize (spread) to distant sites.

Endocrine gland neoplasms can occur in any of the endocrine glands, including:

1. Pituitary gland: located at the base of the brain, it produces several hormones that regulate growth and development, as well as other bodily functions.
2. Thyroid gland: located in the neck, it produces thyroid hormones that regulate metabolism and calcium balance.
3. Parathyroid glands: located near the thyroid gland, they produce parathyroid hormone that regulates calcium levels in the blood.
4. Adrenal glands: located on top of each kidney, they produce hormones such as adrenaline, cortisol, and aldosterone that regulate stress response, metabolism, and blood pressure.
5. Pancreas: located behind the stomach, it produces insulin and glucagon, which regulate blood sugar levels, and digestive enzymes that help break down food.
6. Pineal gland: located in the brain, it produces melatonin, a hormone that regulates sleep-wake cycles.
7. Gonads (ovaries and testicles): located in the pelvis (ovaries) and scrotum (testicles), they produce sex hormones such as estrogen, progesterone, and testosterone that regulate reproductive function and secondary sexual characteristics.

Endocrine gland neoplasms can cause various symptoms depending on the type and location of the tumor. For example, a pituitary gland neoplasm may cause headaches, vision problems, or hormonal imbalances, while an adrenal gland neoplasm may cause high blood pressure, weight gain, or mood changes.

Diagnosis of endocrine gland neoplasms typically involves a combination of medical history, physical examination, imaging studies such as CT or MRI scans, and laboratory tests to measure hormone levels. Treatment options may include surgery, radiation therapy, chemotherapy, or hormonal therapy, depending on the type and stage of the tumor.

Gastrointestinal (GI) neoplasms refer to abnormal growths in the gastrointestinal tract, which can be benign or malignant. The gastrointestinal tract includes the mouth, esophagus, stomach, small intestine, large intestine, rectum, and anus.

Benign neoplasms are non-cancerous growths that do not invade nearby tissues or spread to other parts of the body. They can sometimes be removed completely and may not cause any further health problems.

Malignant neoplasms, on the other hand, are cancerous growths that can invade nearby tissues and organs and spread to other parts of the body through the bloodstream or lymphatic system. These types of neoplasms can be life-threatening if not diagnosed and treated promptly.

GI neoplasms can cause various symptoms, including abdominal pain, bloating, changes in bowel habits, nausea, vomiting, weight loss, and anemia. The specific symptoms may depend on the location and size of the neoplasm.

There are many types of GI neoplasms, including adenocarcinomas, gastrointestinal stromal tumors (GISTs), lymphomas, and neuroendocrine tumors. The diagnosis of GI neoplasms typically involves a combination of medical history, physical examination, imaging studies, and biopsy. Treatment options may include surgery, radiation therapy, chemotherapy, targeted therapy, or immunotherapy.

Pancreatic ductal carcinoma (PDC) is a specific type of cancer that forms in the ducts that carry digestive enzymes out of the pancreas. It's the most common form of exocrine pancreatic cancer, making up about 90% of all cases.

The symptoms of PDC are often vague and can include abdominal pain, jaundice (yellowing of the skin and eyes), unexplained weight loss, and changes in bowel movements. These symptoms can be similar to those caused by other less serious conditions, which can make diagnosis difficult.

Pancreatic ductal carcinoma is often aggressive and difficult to treat. The prognosis for PDC is generally poor, with a five-year survival rate of only about 9%. Treatment options may include surgery, chemotherapy, radiation therapy, or a combination of these approaches. However, because PDC is often not detected until it has advanced, treatment is frequently focused on palliative care to relieve symptoms and improve quality of life.

Experimental neoplasms refer to abnormal growths or tumors that are induced and studied in a controlled laboratory setting, typically in animals or cell cultures. These studies are conducted to understand the fundamental mechanisms of cancer development, progression, and potential treatment strategies. By manipulating various factors such as genetic mutations, environmental exposures, and pharmacological interventions, researchers can gain valuable insights into the complex processes underlying neoplasm formation and identify novel targets for cancer therapy. It is important to note that experimental neoplasms may not always accurately represent human cancers, and further research is needed to translate these findings into clinically relevant applications.

A neoplasm of vascular tissue is an abnormal growth or mass of cells in the blood vessels or lymphatic vessels. These growths can be benign (non-cancerous) or malignant (cancerous). Benign neoplasms, such as hemangiomas and lymphangiomas, are typically not harmful and may not require treatment. However, they can cause symptoms if they grow large enough to press on nearby organs or tissues. Malignant neoplasms, such as angiosarcomas, are cancerous and can invade and destroy surrounding tissue, as well as spread (metastasize) to other parts of the body. Treatment for vascular tissue neoplasms depends on the type, size, location, and stage of the growth, and may include surgery, radiation therapy, chemotherapy, or a combination of these.

Eye neoplasms, also known as ocular tumors or eye cancer, refer to abnormal growths of tissue in the eye. These growths can be benign (non-cancerous) or malignant (cancerous). Eye neoplasms can develop in various parts of the eye, including the eyelid, conjunctiva, cornea, iris, ciliary body, choroid, retina, and optic nerve.

Benign eye neoplasms are typically slow-growing and do not spread to other parts of the body. They may cause symptoms such as vision changes, eye pain, or a noticeable mass in the eye. Treatment options for benign eye neoplasms include monitoring, surgical removal, or radiation therapy.

Malignant eye neoplasms, on the other hand, can grow and spread rapidly to other parts of the body. They may cause symptoms such as vision changes, eye pain, floaters, or flashes of light. Treatment options for malignant eye neoplasms depend on the type and stage of cancer but may include surgery, radiation therapy, chemotherapy, or a combination of these treatments.

It is important to note that early detection and treatment of eye neoplasms can improve outcomes and prevent complications. Regular eye exams with an ophthalmologist are recommended for early detection and prevention of eye diseases, including eye neoplasms.

Immunohistochemistry (IHC) is a technique used in pathology and laboratory medicine to identify specific proteins or antigens in tissue sections. It combines the principles of immunology and histology to detect the presence and location of these target molecules within cells and tissues. This technique utilizes antibodies that are specific to the protein or antigen of interest, which are then tagged with a detection system such as a chromogen or fluorophore. The stained tissue sections can be examined under a microscope, allowing for the visualization and analysis of the distribution and expression patterns of the target molecule in the context of the tissue architecture. Immunohistochemistry is widely used in diagnostic pathology to help identify various diseases, including cancer, infectious diseases, and immune-mediated disorders.

Nose neoplasms refer to abnormal growths or tumors in the nasal cavity or paranasal sinuses. These growths can be benign (non-cancerous) or malignant (cancerous). Benign neoplasms are typically slow-growing and do not spread to other parts of the body, while malignant neoplasms can invade surrounding tissues and have the potential to metastasize.

Nose neoplasms can cause various symptoms such as nasal congestion, nosebleeds, difficulty breathing through the nose, loss of smell, facial pain or numbness, and visual changes if they affect the eye. The diagnosis of nose neoplasms usually involves a combination of physical examination, imaging studies (such as CT or MRI scans), and biopsy to determine the type and extent of the growth. Treatment options depend on the type, size, location, and stage of the neoplasm and may include surgery, radiation therapy, chemotherapy, or a combination of these approaches.

Salivary gland neoplasms refer to abnormal growths or tumors that develop in the salivary glands. These glands are responsible for producing saliva, which helps in digestion, lubrication of food and maintaining oral health. Salivary gland neoplasms can be benign (non-cancerous) or malignant (cancerous).

Benign neoplasms are slow-growing and typically do not spread to other parts of the body. They may cause symptoms such as swelling, painless lumps, or difficulty swallowing if they grow large enough to put pressure on surrounding tissues.

Malignant neoplasms, on the other hand, can be aggressive and have the potential to invade nearby structures and metastasize (spread) to distant organs. Symptoms of malignant salivary gland neoplasms may include rapid growth, pain, numbness, or paralysis of facial nerves.

Salivary gland neoplasms can occur in any of the major salivary glands (parotid, submandibular, and sublingual glands) or in the minor salivary glands located throughout the mouth and throat. The exact cause of these neoplasms is not fully understood, but risk factors may include exposure to radiation, certain viral infections, and genetic predisposition.

Radiation-induced neoplasms are a type of cancer or tumor that develops as a result of exposure to ionizing radiation. Ionizing radiation is radiation with enough energy to remove tightly bound electrons from atoms or molecules, leading to the formation of ions. This type of radiation can damage DNA and other cellular structures, which can lead to mutations and uncontrolled cell growth, resulting in the development of a neoplasm.

Radiation-induced neoplasms can occur after exposure to high levels of ionizing radiation, such as that received during radiation therapy for cancer treatment or from nuclear accidents. The risk of developing a radiation-induced neoplasm depends on several factors, including the dose and duration of radiation exposure, the type of radiation, and the individual's genetic susceptibility to radiation-induced damage.

Radiation-induced neoplasms can take many years to develop after initial exposure to ionizing radiation, and they often occur at the site of previous radiation therapy. Common types of radiation-induced neoplasms include sarcomas, carcinomas, and thyroid cancer. It is important to note that while ionizing radiation can increase the risk of developing cancer, the overall risk is still relatively low, especially when compared to other well-established cancer risk factors such as smoking and exposure to certain chemicals.

Adenocarcinoma, papillary is a type of cancer that begins in the glandular cells and grows in a finger-like projection (called a papilla). This type of cancer can occur in various organs, including the lungs, pancreas, thyroid, and female reproductive system. The prognosis and treatment options for papillary adenocarcinoma depend on several factors, such as the location and stage of the tumor, as well as the patient's overall health. It is important to consult with a healthcare professional for an accurate diagnosis and personalized treatment plan.

Carcinoma, papillary is a type of cancer that begins in the cells that line the glandular structures or the lining of organs. In a papillary carcinoma, the cancerous cells grow and form small finger-like projections, called papillae, within the tumor. This type of cancer most commonly occurs in the thyroid gland, but can also be found in other organs such as the lung, breast, and kidney. Papillary carcinoma of the thyroid gland is usually slow-growing and has a good prognosis, especially when it is diagnosed at an early stage.

Testicular neoplasms are abnormal growths or tumors in the testicle that can be benign (non-cancerous) or malignant (cancerous). They are a type of genitourinary cancer, which affects the reproductive and urinary systems. Testicular neoplasms can occur in men of any age but are most commonly found in young adults between the ages of 15 and 40.

Testicular neoplasms can be classified into two main categories: germ cell tumors and non-germ cell tumors. Germ cell tumors, which arise from the cells that give rise to sperm, are further divided into seminomas and non-seminomas. Seminomas are typically slow-growing and have a good prognosis, while non-seminomas tend to grow more quickly and can spread to other parts of the body.

Non-germ cell tumors are less common than germ cell tumors and include Leydig cell tumors, Sertoli cell tumors, and lymphomas. These tumors can have a variety of clinical behaviors, ranging from benign to malignant.

Testicular neoplasms often present as a painless mass or swelling in the testicle. Other symptoms may include a feeling of heaviness or discomfort in the scrotum, a dull ache in the lower abdomen or groin, and breast enlargement (gynecomastia).

Diagnosis typically involves a physical examination, imaging studies such as ultrasound or CT scan, and blood tests to detect tumor markers. Treatment options depend on the type and stage of the neoplasm but may include surgery, radiation therapy, chemotherapy, or a combination of these modalities. Regular self-examinations of the testicles are recommended for early detection and improved outcomes.

Neoplasms in muscle tissue refer to abnormal and excessive growths of muscle cells that can be benign or malignant. These growths can arise from any of the three types of muscle tissue: skeletal, cardiac, or smooth muscle. Neoplasms in muscle tissue are classified based on their origin, behavior, and histological features.

Benign neoplasms in muscle tissue include leiomyomas (smooth muscle), rhabdomyomas (skeletal muscle), and myxomas (cardiac muscle). These tumors are usually slow-growing and do not invade surrounding tissues or spread to other parts of the body.

Malignant neoplasms in muscle tissue, also known as sarcomas, include leiomyosarcoma (smooth muscle), rhabdomyosarcoma (skeletal muscle), and angiosarcoma (cardiac muscle). These tumors are aggressive, invasive, and have the potential to metastasize to other parts of the body.

Symptoms of neoplasms in muscle tissue depend on their location, size, and type. They may include a painless or painful mass, weakness, fatigue, weight loss, and difficulty swallowing or breathing. Treatment options for neoplasms in muscle tissue include surgery, radiation therapy, chemotherapy, and targeted therapy. The choice of treatment depends on the type, stage, location, and patient's overall health condition.

Neoplasms are abnormal growths of cells or tissues that serve no purpose and can be benign (non-cancerous) or malignant (cancerous). Glandular and epithelial neoplasms refer to specific types of tumors that originate from the glandular and epithelial tissues, respectively.

Glandular neoplasms arise from the glandular tissue, which is responsible for producing and secreting substances such as hormones, enzymes, or other fluids. These neoplasms can be further classified into adenomas (benign) and adenocarcinomas (malignant).

Epithelial neoplasms, on the other hand, develop from the epithelial tissue that lines the outer surfaces of organs and the inner surfaces of cavities. These neoplasms can also be benign or malignant and are classified as papillomas (benign) and carcinomas (malignant).

It is important to note that while both glandular and epithelial neoplasms can become cancerous, not all of them do. However, if they do, the malignant versions can invade surrounding tissues and spread to other parts of the body, making them potentially life-threatening.

Mucinous cystadenocarcinoma is a type of cancer that arises from the mucin-producing cells in the lining of a cyst. It is a subtype of cystadenocarcinoma, which is a malignant tumor that develops within a cyst. Mucinous cystadenocarcinomas are typically found in the ovary or pancreas but can also occur in other organs such as the appendix and the respiratory tract.

These tumors are characterized by the production of large amounts of mucin, a gel-like substance that can accumulate within the cyst and cause it to grow. Mucinous cystadenocarcinomas tend to grow slowly but can become quite large and may eventually spread (metastasize) to other parts of the body if left untreated.

Symptoms of mucinous cystadenocarcinoma depend on the location and size of the tumor, but they may include abdominal pain or discomfort, bloating, changes in bowel movements, or vaginal bleeding. Treatment typically involves surgical removal of the tumor, followed by chemotherapy or radiation therapy to kill any remaining cancer cells. The prognosis for mucinous cystadenocarcinoma depends on several factors, including the stage of the disease at diagnosis and the patient's overall health.

An adenoma is a benign (noncancerous) tumor that develops from glandular epithelial cells. These types of cells are responsible for producing and releasing fluids, such as hormones or digestive enzymes, into the surrounding tissues. Adenomas can occur in various organs and glands throughout the body, including the thyroid, pituitary, adrenal, and digestive systems.

Depending on their location, adenomas may cause different symptoms or remain asymptomatic. Some common examples of adenomas include:

1. Colorectal adenoma (also known as a polyp): These growths occur in the lining of the colon or rectum and can develop into colorectal cancer if left untreated. Regular screenings, such as colonoscopies, are essential for early detection and removal of these polyps.
2. Thyroid adenoma: This type of adenoma affects the thyroid gland and may result in an overproduction or underproduction of hormones, leading to conditions like hyperthyroidism (overactive thyroid) or hypothyroidism (underactive thyroid).
3. Pituitary adenoma: These growths occur in the pituitary gland, which is located at the base of the brain and controls various hormonal functions. Depending on their size and location, pituitary adenomas can cause vision problems, headaches, or hormonal imbalances that affect growth, reproduction, and metabolism.
4. Liver adenoma: These rare benign tumors develop in the liver and may not cause any symptoms unless they become large enough to press on surrounding organs or structures. In some cases, liver adenomas can rupture and cause internal bleeding.
5. Adrenal adenoma: These growths occur in the adrenal glands, which are located above the kidneys and produce hormones that regulate stress responses, metabolism, and blood pressure. Most adrenal adenomas are nonfunctioning, meaning they do not secrete excess hormones. However, functioning adrenal adenomas can lead to conditions like Cushing's syndrome or Conn's syndrome, depending on the type of hormone being overproduced.

It is essential to monitor and manage benign tumors like adenomas to prevent potential complications, such as rupture, bleeding, or hormonal imbalances. Treatment options may include surveillance with imaging studies, medication to manage hormonal issues, or surgical removal of the tumor in certain cases.

Soft tissue neoplasms refer to abnormal growths or tumors that develop in the soft tissues of the body. Soft tissues include muscles, tendons, ligaments, fascia, nerves, blood vessels, fat, and synovial membranes (the thin layer of cells that line joints and tendons). Neoplasms can be benign (non-cancerous) or malignant (cancerous), and their behavior and potential for spread depend on the specific type of neoplasm.

Benign soft tissue neoplasms are typically slow-growing, well-circumscribed, and rarely spread to other parts of the body. They can often be removed surgically with a low risk of recurrence. Examples of benign soft tissue neoplasms include lipomas (fat tumors), schwannomas (nerve sheath tumors), and hemangiomas (blood vessel tumors).

Malignant soft tissue neoplasms, on the other hand, can grow rapidly, invade surrounding tissues, and may metastasize (spread) to distant parts of the body. They are often more difficult to treat than benign neoplasms and require a multidisciplinary approach, including surgery, radiation therapy, and chemotherapy. Examples of malignant soft tissue neoplasms include sarcomas, such as rhabdomyosarcoma (arising from skeletal muscle), leiomyosarcoma (arising from smooth muscle), and angiosarcoma (arising from blood vessels).

It is important to note that soft tissue neoplasms can occur in any part of the body, and their diagnosis and treatment require a thorough evaluation by a healthcare professional with expertise in this area.

Hematologic neoplasms, also known as hematological malignancies, are a group of diseases characterized by the uncontrolled growth and accumulation of abnormal blood cells or bone marrow cells. These disorders can originate from the myeloid or lymphoid cell lines, which give rise to various types of blood cells, including red blood cells, white blood cells, and platelets.

Hematologic neoplasms can be broadly classified into three categories:

1. Leukemias: These are cancers that primarily affect the bone marrow and blood-forming tissues. They result in an overproduction of abnormal white blood cells, which interfere with the normal functioning of the blood and immune system. There are several types of leukemia, including acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), and chronic myeloid leukemia (CML).
2. Lymphomas: These are cancers that develop from the lymphatic system, which is a part of the immune system responsible for fighting infections. Lymphomas can affect lymph nodes, spleen, bone marrow, and other organs. The two main types of lymphoma are Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL).
3. Myelomas: These are cancers that arise from the plasma cells, a type of white blood cell responsible for producing antibodies. Multiple myeloma is the most common type of myeloma, characterized by an excessive proliferation of malignant plasma cells in the bone marrow, leading to the production of abnormal amounts of monoclonal immunoglobulins (M proteins) and bone destruction.

Hematologic neoplasms can have various symptoms, such as fatigue, weakness, frequent infections, easy bruising or bleeding, weight loss, swollen lymph nodes, and bone pain. The diagnosis typically involves a combination of medical history, physical examination, laboratory tests, imaging studies, and sometimes bone marrow biopsy. Treatment options depend on the type and stage of the disease and may include chemotherapy, radiation therapy, targeted therapy, immunotherapy, stem cell transplantation, or a combination of these approaches.

A neoplasm is a tumor or growth that is formed by an abnormal and excessive proliferation of cells, which can be benign or malignant. Neoplasm proteins are therefore any proteins that are expressed or produced in these neoplastic cells. These proteins can play various roles in the development, progression, and maintenance of neoplasms.

Some neoplasm proteins may contribute to the uncontrolled cell growth and division seen in cancer, such as oncogenic proteins that promote cell cycle progression or inhibit apoptosis (programmed cell death). Others may help the neoplastic cells evade the immune system, allowing them to proliferate undetected. Still others may be involved in angiogenesis, the formation of new blood vessels that supply the tumor with nutrients and oxygen.

Neoplasm proteins can also serve as biomarkers for cancer diagnosis, prognosis, or treatment response. For example, the presence or level of certain neoplasm proteins in biological samples such as blood or tissue may indicate the presence of a specific type of cancer, help predict the likelihood of cancer recurrence, or suggest whether a particular therapy will be effective.

Overall, understanding the roles and behaviors of neoplasm proteins can provide valuable insights into the biology of cancer and inform the development of new diagnostic and therapeutic strategies.

Uterine neoplasms refer to abnormal growths in the uterus, which can be benign (non-cancerous) or malignant (cancerous). These growths can originate from different types of cells within the uterus, leading to various types of uterine neoplasms. The two main categories of uterine neoplasms are endometrial neoplasms and uterine sarcomas.

Endometrial neoplasms develop from the endometrium, which is the inner lining of the uterus. Most endometrial neoplasms are classified as endometrioid adenocarcinomas, arising from glandular cells in the endometrium. Other types include serous carcinoma, clear cell carcinoma, and mucinous carcinoma.

Uterine sarcomas, on the other hand, are less common and originate from the connective tissue (stroma) or muscle (myometrium) of the uterus. Uterine sarcomas can be further divided into several subtypes, such as leiomyosarcoma, endometrial stromal sarcoma, and undifferentiated uterine sarcoma.

Uterine neoplasms can cause various symptoms, including abnormal vaginal bleeding or discharge, pelvic pain, and difficulty urinating or having bowel movements. The diagnosis typically involves a combination of imaging tests (such as ultrasound, CT, or MRI scans) and tissue biopsies to determine the type and extent of the neoplasm. Treatment options depend on the type, stage, and patient's overall health but may include surgery, radiation therapy, chemotherapy, or hormone therapy.

Intestinal neoplasms refer to abnormal growths in the tissues of the intestines, which can be benign or malignant. These growths are called neoplasms and they result from uncontrolled cell division. In the case of intestinal neoplasms, these growths occur in the small intestine, large intestine (colon), rectum, or appendix.

Benign intestinal neoplasms are not cancerous and often do not invade surrounding tissues or spread to other parts of the body. However, they can still cause problems if they grow large enough to obstruct the intestines or cause bleeding. Common types of benign intestinal neoplasms include polyps, leiomyomas, and lipomas.

Malignant intestinal neoplasms, on the other hand, are cancerous and can invade surrounding tissues and spread to other parts of the body. The most common type of malignant intestinal neoplasm is adenocarcinoma, which arises from the glandular cells lining the inside of the intestines. Other types of malignant intestinal neoplasms include lymphomas, sarcomas, and carcinoid tumors.

Symptoms of intestinal neoplasms can vary depending on their size, location, and type. Common symptoms include abdominal pain, bloating, changes in bowel habits, rectal bleeding, weight loss, and fatigue. If you experience any of these symptoms, it is important to seek medical attention promptly.

Neoplasms, adnexal and skin appendage refer to abnormal growths or tumors that develop in the sweat glands, hair follicles, or other structures associated with the skin. These growths can be benign (non-cancerous) or malignant (cancerous), and they can occur anywhere on the body.

Adnexal neoplasms are tumors that arise from the sweat glands or hair follicles, including the sebaceous glands, eccrine glands, and apocrine glands. These tumors can range in size and severity, and they may cause symptoms such as pain, itching, or changes in the appearance of the skin.

Skin appendage neoplasms are similar to adnexal neoplasms, but they specifically refer to tumors that arise from structures such as hair follicles, nails, and sweat glands. Examples of skin appendage neoplasms include pilomatricomas (tumors of the hair follicle), trichilemmomas (tumors of the outer root sheath of the hair follicle), and sebaceous adenomas (tumors of the sebaceous glands).

It is important to note that while many adnexal and skin appendage neoplasms are benign, some can be malignant and may require aggressive treatment. If you notice any unusual growths or changes in your skin, it is important to consult with a healthcare professional for further evaluation and care.

Neoplasm staging is a systematic process used in medicine to describe the extent of spread of a cancer, including the size and location of the original (primary) tumor and whether it has metastasized (spread) to other parts of the body. The most widely accepted system for this purpose is the TNM classification system developed by the American Joint Committee on Cancer (AJCC) and the Union for International Cancer Control (UICC).

In this system, T stands for tumor, and it describes the size and extent of the primary tumor. N stands for nodes, and it indicates whether the cancer has spread to nearby lymph nodes. M stands for metastasis, and it shows whether the cancer has spread to distant parts of the body.

Each letter is followed by a number that provides more details about the extent of the disease. For example, a T1N0M0 cancer means that the primary tumor is small and has not spread to nearby lymph nodes or distant sites. The higher the numbers, the more advanced the cancer.

Staging helps doctors determine the most appropriate treatment for each patient and estimate the patient's prognosis. It is an essential tool for communication among members of the healthcare team and for comparing outcomes of treatments in clinical trials.

Vascular neoplasms are a type of tumor that develops from cells that line the blood vessels or lymphatic vessels. These tumors can be benign (non-cancerous) or malignant (cancerous). Benign vascular neoplasms, such as hemangiomas and lymphangiomas, are usually harmless and may not require treatment unless they cause symptoms or complications. Malignant vascular neoplasms, on the other hand, are known as angiosarcomas and can be aggressive, spreading to other parts of the body and potentially causing serious health problems.

Angiosarcomas can develop in any part of the body but are most commonly found in the skin, particularly in areas exposed to radiation or chronic lymph edema. They can also occur in the breast, liver, spleen, and heart. Treatment for vascular neoplasms depends on the type, location, size, and stage of the tumor, as well as the patient's overall health. Treatment options may include surgery, radiation therapy, chemotherapy, or a combination of these approaches.

Sweat gland neoplasms are abnormal growths that develop in the sweat glands. These growths can be benign (noncancerous) or malignant (cancerous). Benign sweat gland neoplasms include hidradenomas and syringomas, which are usually slow-growing and cause little to no symptoms. Malignant sweat gland neoplasms, also known as sweat gland carcinomas, are rare but aggressive cancers that can spread to other parts of the body. They may cause symptoms such as a lump or mass under the skin, pain, swelling, and redness. Treatment typically involves surgical removal of the growth.

Lymphoma is a type of cancer that originates from the white blood cells called lymphocytes, which are part of the immune system. These cells are found in various parts of the body such as the lymph nodes, spleen, bone marrow, and other organs. Lymphoma can be classified into two main types: Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL).

HL is characterized by the presence of a specific type of abnormal lymphocyte called Reed-Sternberg cells, while NHL includes a diverse group of lymphomas that lack these cells. The symptoms of lymphoma may include swollen lymph nodes, fever, night sweats, weight loss, and fatigue.

The exact cause of lymphoma is not known, but it is believed to result from genetic mutations in the lymphocytes that lead to uncontrolled cell growth and division. Exposure to certain viruses, chemicals, and radiation may increase the risk of developing lymphoma. Treatment options for lymphoma depend on various factors such as the type and stage of the disease, age, and overall health of the patient. Common treatments include chemotherapy, radiation therapy, immunotherapy, and stem cell transplantation.

Bone neoplasms are abnormal growths or tumors that develop in the bone. They can be benign (non-cancerous) or malignant (cancerous). Benign bone neoplasms do not spread to other parts of the body and are rarely a threat to life, although they may cause problems if they grow large enough to press on surrounding tissues or cause fractures. Malignant bone neoplasms, on the other hand, can invade and destroy nearby tissue and may spread (metastasize) to other parts of the body.

There are many different types of bone neoplasms, including:

1. Osteochondroma - a benign tumor that develops from cartilage and bone
2. Enchondroma - a benign tumor that forms in the cartilage that lines the inside of the bones
3. Chondrosarcoma - a malignant tumor that develops from cartilage
4. Osteosarcoma - a malignant tumor that develops from bone cells
5. Ewing sarcoma - a malignant tumor that develops in the bones or soft tissues around the bones
6. Giant cell tumor of bone - a benign or occasionally malignant tumor that develops from bone tissue
7. Fibrosarcoma - a malignant tumor that develops from fibrous tissue in the bone

The symptoms of bone neoplasms vary depending on the type, size, and location of the tumor. They may include pain, swelling, stiffness, fractures, or limited mobility. Treatment options depend on the type and stage of the tumor but may include surgery, radiation therapy, chemotherapy, or a combination of these treatments.

Palatal neoplasms refer to abnormal growths or tumors that occur on the palate, which is the roof of the mouth. These growths can be benign (non-cancerous) or malignant (cancerous). Benign neoplasms are typically slower growing and less likely to spread, while malignant neoplasms are more aggressive and can invade nearby tissues and organs.

Palatal neoplasms can have various causes, including genetic factors, environmental exposures, and viral infections. They may present with symptoms such as mouth pain, difficulty swallowing, swelling or lumps in the mouth, bleeding, or numbness in the mouth or face.

The diagnosis of palatal neoplasms typically involves a thorough clinical examination, imaging studies, and sometimes biopsy to determine the type and extent of the growth. Treatment options depend on the type, size, location, and stage of the neoplasm but may include surgery, radiation therapy, chemotherapy, or a combination of these approaches. Regular follow-up care is essential to monitor for recurrence or spread of the neoplasm.

... anal gland neoplasms MeSH C04.588.274.476.411.445 - duodenal neoplasms MeSH C04.588.274.476.411.501 - ileal neoplasms MeSH ... skull base neoplasms MeSH C04.588.149.828 - spinal neoplasms MeSH C04.588.180.260 - breast neoplasms, male MeSH C04.588.180.390 ... bile duct neoplasms MeSH C04.588.274.120.250.250 - common bile duct neoplasms MeSH C04.588.274.120.401 - gallbladder neoplasms ... femoral neoplasms MeSH C04.588.149.721 - skull neoplasms MeSH C04.588.149.721.450 - jaw neoplasms MeSH C04.588.149.721.450.583 ...
... anus neoplasms MeSH C06.301.371.411.307.790.040.040 - anal gland neoplasms MeSH C06.301.371.411.445 - duodenal neoplasms MeSH ... anus neoplasms MeSH C06.405.249.411.307.790.040.040 - anal gland neoplasms MeSH C06.405.249.411.445 - duodenal neoplasms MeSH ... anus neoplasms MeSH C06.405.469.491.307.790.040.040 - anal gland neoplasms MeSH C06.405.469.491.445 - duodenal neoplasms MeSH ... sigmoid neoplasms MeSH C06.405.469.275 - duodenal diseases MeSH C06.405.469.275.270 - duodenal neoplasms MeSH C06.405.469.275. ...
... coloboma talipes Esophageal atresia Esophageal disorder Esophageal duodenal atresia abnormalities of hands Esophageal neoplasm ...
... duodenal tumor. Small intestine: small intestine neoplasms, smooth muscle tumors, sarcomas, polyps, lymphomas, inflammation, ... Stomach and duodenum: chronic gastritis, gastric ulcer, benign gastric tumor, gastric cancer, duodenal ulcer, ...
... familial Pancreatic diseases Pancreatic islet cell neoplasm Pancreatic islet cell tumors Pancreatic lipomatosis duodenal ... et varioliformis acuta Pityriasis rubra pilaris Piussan-Lenaerts-Mathieu syndrome Placenta disorder Placenta neoplasm Placental ... retardation-hyperkeratosis Parapsoriasis Parasitophobia Parastremmatic dwarfism Parathyroid cancer Parathyroid neoplasm ...
... congenital or genetic conditions Duodenal (intestinal) atresia Hirschsprung's disease Meckel's diverticulum Pyloric stenosis ... Viral infections Rotavirus Norovirus Astrovirus Adenovirus Calicivirus Neoplasms (cancers) Adenocarcinoma Carcinoid ... artery or the superior mesenteric vein Arteriovenous malformation Gastric dumping syndrome Irritable bowel syndrome Duodenal ( ...
They may include aneuploidies, structural abnormalities, or neoplasms. Acardiac twin Achondrogenesis Achondroplasia Adrenal ... Cystic hygroma Dandy-Walker malformation Diaphragmatic hernia Diastrophic dysplasia Double outlet right ventricle Duodenal ...
CEBPA mutation Myeloid neoplasms with germline DDX41 mutation Myeloid neoplasms with germline RUNX1 mutation Myeloid neoplasms ... Nodal marginal zone lymphoma Paediatric nodal marginal zone lymphoma Follicular lymphoma In situ follicular neoplasia Duodenal- ... neoplasms with PDGFRA rearrangement Myeloid/lymphoid neoplasms with PDGFRB rearrangement Myeloid/lymphoid neoplasms with FGFR1 ... NOS Lymphoid neoplasms Precursor lymphoid neoplasms B-lymphoblastic leukaemia/lymphoma, NOS B-lymphoblastic leukaemia/lymphoma ...
The L249P kindred also had one family member with renal cell carcinoma and another family member with Duodenal cancer. The ... One patient with ETV6-FLT3-related myeloid/lymphoid neoplasm obtained a short term remission on sunitinib and following relapse ... Reiter A, Gotlib J (February 2017). "Myeloid neoplasms with eosinophilia". Blood. 129 (6): 704-714. doi:10.1182/blood-2016-10- ... myeloproliferative neoplasm (MPN), and acute myeloid leukemia (AML). The presence of ETV6 gene mutations in myelodysplastic ...
Duodenal ulceration can lead to inflammation or fibrosis of the duodenum. Duodenal scarring or blockage makes it subpar for an ... Gore RM, Shelhamer RP (October 2007). "Biliary tract neoplasms: diagnosis and staging". Cancer Imaging. 7 Spec No A (Special ... The longitudinal duodenal cut should be located slightly inferior to the choledochotomy. As the small intestine is known to ... Biliary/Duodenal Bypass Procedures. 2 (4): 304-310. doi:10.1053/otgn.2000.19143. ISSN 1524-153X. Baker RJ (2001). Mastery of ...
Marks E, Shi Y (April 2018). "Duodenal-Type Follicular Lymphoma: A Clinicopathologic Review". Archives of Pathology & ... 2022). "The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms". ... "Recent progress in follicular lymphoma in Japan and characteristics of the duodenal type". Pathology International. 68 (12): ... "The 2016 revision of the World Health Organization classification of lymphoid neoplasms". Blood. 127 (20): 2375-90. doi:10.1182 ...
Patients with gastrinomas that are also known to be part of neuroendocrine neoplasms must have to deal with two factors related ... Secretin, which is a hormone released from the duodenal S cells that induce the release of pancreatic bicarbonate (HCO3) that ... The excessive gastric acid output breaches the mucosal defenses of the gastric as well as the duodenal wall, causes ulceration ... arise as primary neoplasms in lymph nodes of the pancreaticoduodenal region (gastrinoma triangle). Most gastrinomas are ...
... gastrointestinal Colon cancer Duodenal cancer Extrahepatic bile duct cancer Gallbladder cancer Gastric (stomach) cancer ... Marginal zone B-cell lymphoma Mast cell leukemia Mediastinal large B cell lymphoma Multiple myeloma/plasma cell neoplasm ...
Sometimes a direct drainage across the stomach or duodenal wall is used instead. The transpapillary approach is used when the ... The CT scan's weakness is its lack of differentiation between pseudocysts and cystic neoplasm. Also, the intravenous contrast ... Transgastric or transduodenal approaches are used when the pseudocyst is next to the gastro-duodenal wall. Endoscopic ...
Spivach A, Borea B, Bertoli G, Daris G (July 1976). "[Primary lung neoplasm of rare incidence: giant cell carcinoma]". Minerva ... Carstens PH, Broghamer WL (April 1978). "Duodenal carcinoid with cytoplasmic whorls of microfilaments". J. Pathol. 124 (4): 235 ... The new paradigm recognizes that lung cancers are a large and extremely heterogeneous family of malignant neoplasms, with over ... Travis WD (November 2010). "Sarcomatoid neoplasms of the lung and pleura". Arch. Pathol. Lab. Med. 134 (11): 1645-58. doi: ...
Jejunal, duodenal mucosa or Brunner's tissue were each found in 2% of ectopic cases. Heterotopic rests of gastric mucosa and ... Abscess formation in the abdominal wall Fibrous cord increases the risk of volvulus formation and internal herniation Neoplasms ...
Substances may also be placed into the small intestines, as with a duodenal feeding tube and enteral nutrition. Enteric coated ... Intraocular, into the eye, e.g., some medications for glaucoma or eye neoplasms. Intraosseous infusion (into the bone marrow) ...
... is a neoplasm (neoplasia) originating from mast cells in the domestic dog, which occurs mainly in the skin ... tarry stools and anemia occur as a result of gastric or duodenal ulcers, in autopsies such ulcers are even detected in more ... G. A. Parker, C. A. Picut: Histopathologic features and post-surgical sequelae of 57 cutaneous neoplasms in ferrets (Mustela ... Apparently, mastocytomas in dogs are molecularly heterogeneous neoplasms. Mastocytomas in the German Boxer, one of the most ...
... definitive diagnosis is by identification of eggs by microscopic demonstration in faeces or in duodenal aspirate, but other ... and can eventually lead to intraductal papillary mucinous neoplasm or cholangiocarcinoma. With RPC, the gallstones found within ...
Detailed examination of duodenal walls and folds, colonic walls and haustra was performed using a 7.5 MHz probe. Deeply located ... and left-sided colorectal neoplasms after colonoscopy: population-based study". J Natl Cancer Inst. 102 (2): 89-95. doi:10.1093 ...
... dystrophy Duhring-Brocq disease Duhring's disease Duker-Weiss-Siber syndrome Duodenal atresia tetralogy of Fallot Duodenal ... Dent disease Dental aberrations steroid dehydrogenase deficienciency Dental caries Dental fluorosis Dental tissue neoplasm ...
American Cancer Society, 2023) Small intestine cancer can be subdivided into duodenal cancer (the first part of the small ... Malignant Neoplasms of the Small Intestine. eMedicine.com. URL: http://www.emedicine.com/MED/topic2651.htm. Accessed on: June 2 ... intestine) and cancer of the jejunum and ileum (the latter two parts of the small intestine). Duodenal cancer has more in ...
Baranov E, Hornick JL (March 2020). "Soft Tissue Special Issue: Fibroblastic and Myofibroblastic Neoplasms of the Head and Neck ... familial polyposis may manifest as polyps in colon or in the duodenal tract, or in any combination of these. Therefore, an ... to search for premalignant gastric or duodenal cancers), typically once every 1-3 years, and/or a genetic blood test to ...
Bleeding that occurs due to a neoplasm (cancer growth) can be treated using colonoscopy and clipping, surgical intervention, or ... Peptic ulcer disease-divided into either duodenal or gastric ulcers, most common causes include: Non steroidal anti- ...
Inflammation of the pyloric antrum, which connects the stomach to the duodenum, is more likely to lead to duodenal ulcers, ... March 2008). "Prevalence of nonpolypoid (flat and depressed) colorectal neoplasms in asymptomatic and symptomatic adults". JAMA ... In 1994, the National Institutes of Health stated most recurrent duodenal and gastric ulcers were caused by H. pylori, and ... Helicobacter pylori harms the stomach and duodenal linings by several mechanisms. The ammonia produced to regulate pH is toxic ...
Hypopituitarism commonly develops after radiation therapy for sellar and parasellar neoplasms, extrasellar brain tumours, head ... or duodenal ulcers This collateral radiation is commonly caused by non-targeted delivery (reflux) of the radioactive agents ...
Misago N, Narisawa Y (September 2006). "Cytokeratin 15 expression in neoplasms with sebaceous differentiation". Journal of ... intestinal isografts from normal and transgenic mice to study the programming of positional information along the duodenal-to- ...
The pancreas forms during development from two buds that arise from the duodenal part of the foregut, an embryonic tube that is ... Patil TB, Shrikhande SV, Kanhere HA, Saoji RR, Ramadwar MR, Shukla PJ (2006). "Solid pseudopapillary neoplasm of the pancreas: ... This may be associated with duodenal atresia. 10,000 protein coding genes (~50% of all human genes) are expressed in the normal ... this duct opens into the minor duodenal papilla. If the two buds themselves, each having a duct, do not fuse, a pancreas may ...
... also EATL is the most common neoplasm. Squamous carcinoma of the esophagus is more prevalent in coeliac disease. The increased ... "Increased Prevalence of Anti-Gliadin IgA-Antibodies with Aberrant Duodenal Histopathological Findings in Patients with IgA- ...
Papillary - In oncology, papillary refers to neoplasms with projections ("papillae", from Latin, 'nipple') that have ... in extensive series of coeliac patients have clearly shown that TG2A sensitivity varies depending on the severity of duodenal ...
ClinicalTrials.gov: Duodenal Neoplasms (National Institutes of Health) * ClinicalTrials.gov: Gastrointestinal Stromal Tumors ( ...
... of all new digestive tract neoplasms in the United States. However, cancer of the pancreas is significantly more common, being ... Primary duodenal neoplasms: a retrospective clinico-pathological analysis. World J Gastroenterol. 2007 Feb 21. 13(7):1108-11. [ ... 34, 35] The tumor may spread locally to the duodenal wall, pancreas, or bile duct, or it may spread by metastases to local and ... Duodenal carcinoids account for only 1%-5% of the total. Fewer than 40 cases of ampullary carcinoids exist in the world ...
Endoscopic mucosal resection under gel immersion for superficial nonampullary duodenal epithelial neoplasms * Full Text ... Feng, Yilong; Guan, Liwen; Ye, Liansong; Hu, Bing: Two intraluminal duodenal diverticula treated with a "clip-assisted incision ... Leal, Carina; Dano, Helene; Belkhir, Leila; Deprez, Pierre H.: Actinomycosis associated with a permanently implanted duodenal ... of prophylactic endoscopic clipping for prevention of delayed bleeding after endoscopic papillectomy for ampullary neoplasm: a ...
Adenocarcinoma with intraductal papillary mucinous neoplasm arising in a duodenal heterotopic pancreas: a case report. Clinical ... Intraductal Papillary Mucinous Neoplasms in Hereditary Cancer Syndromes. Biomedicines 2022; 10(7): 1475 doi: 10.3390/ ... Intraductal papillary mucinous neoplasm originating from a heterotopic pancreas within the jejunum: a case report. Journal of ... Intraductal Papillary Mucinous Neoplasm Arising from Heterotopic Pancreas in Stomach: A Case Report and Review of Literature. ...
... of all malignant duodenal neoplasms are duodenal lymphomas [3]. The recognized risk factors include immunodeficiency states, ... Duodenal malignancies presenting with jaundice due to extrahepatic biliary obstruction occur in 43% of cases, but the exact ... This duodenal thickening caused biliary and pancreatic ducts dilatation. The circumferential mass did not invade other organs ... One of the most common presentations is a diffuse circumferential bulky mass in the duodenal wall, involving a relatively long ...
... anal gland neoplasms MeSH C04.588.274.476.411.445 - duodenal neoplasms MeSH C04.588.274.476.411.501 - ileal neoplasms MeSH ... skull base neoplasms MeSH C04.588.149.828 - spinal neoplasms MeSH C04.588.180.260 - breast neoplasms, male MeSH C04.588.180.390 ... bile duct neoplasms MeSH C04.588.274.120.250.250 - common bile duct neoplasms MeSH C04.588.274.120.401 - gallbladder neoplasms ... femoral neoplasms MeSH C04.588.149.721 - skull neoplasms MeSH C04.588.149.721.450 - jaw neoplasms MeSH C04.588.149.721.450.583 ...
Introduction: Duodenal neuroendocrine neoplasms (dNENs) are heterogeneous tumors that can exhibit aggressive behavior, with ... 2760 Management and Outcomes of Duodenal Neuroendocrine Tumours Introduction: Duodenal NENs (D-NENs) are increasing in ... Introduction: There is a substantial clinical unmet need for an accurate blood biomarker for neuroendocrine neoplasms (NENs). ... Introduction: Physiological pancreatico-duodenal DOTA-Exendin-4 uptake in the Brunners glands of the proximal duodenum occurs ...
Endoscopic and surgical management of nonampullary duodenal neoplasms. Surgical endoscopy, 32(6):2859-69, 2018. ...
... cecal neoplasms/ or exp *duodenal neoplasms/ or exp *ileal neoplasms/ or exp *jejunal neoplasms/ or exp *stomach neoplasms/ or ... cecal neoplasms/ or exp *duodenal neoplasms/ or exp *ileal neoplasms/ or exp *jejunal neoplasms/ or exp *stomach neoplasms/ or ... pc or exp COLONIC NEOPLASMS/pc or exp SIGMOID NEOPLASMS/pc or exp RECTAL NEOPLASMS/pc or exp ANUS NEOPLASMS/pc or exp NEOPLASMS ... exp CERVIX NEOPLASMS/pc or exp UTERINE NEOPLASMS/pc or exp VAGINAL NEOPLASMS/pc or exp GENITAL NEOPLASMS, FEMALE/pc or exp ...
Query Trace: Duodenal Neoplasms and TP53[original query]. APC:T1556fs and STK11 mutations in duodenal adenomas and ...
Duodenal transection if PPPD permissible. In concordance with accepted oncologic principles, bulky neoplasms of the pancreatic ... Neoplasms of the Endocrine Pancreas * Quiz: Do You Know the Risk Factors, Diagnostic Tests, and Treatment for Pancreatic Cancer ... The head of the pancreas lies in the duodenal C loop in front of the inferior vena cava (IVC) and the left renal vein (see the ... Resection for neoplasms of the pancreas (proximal resection). Clavien PA, Sarr MG, Fong Y, eds. Atlas of Upper Gastrointestinal ...
A collective term for precoordinated organ/neoplasm headings locating neoplasms by organ, as BRAIN NEOPLASMS; DUODENAL ... NEOPLASMS; LIVER NEOPLASMS; etc.. Synonyms:. exact_synonym: Neoplasm Site; Neoplasm Sites; Neoplasms by Sites. ...
Clip-guided local duodenectomy for safe and minimal local resection of nonampullary duodenal neoplasms Local duodenectomy and ... primary closure is a simple option for some nonampullary duodenal neoplasms. Minimizing the resection area while ensuring ... 3D-printed hemipelvic prosthesis combined with a dual mobility bearing in patients with primary malignant neoplasm involving ... curability is necessary for safe primary duodenal closure. Howev... Authors: Takeshi Miwa, Suguru Yamada, Kazuto Shibuya, ...
A case of cholecystoduodenal fistula mimicking duodenal cancer directly observed by image-enhanced endoscopy. Hayashi, Y., ... Closure of large mucosal defects for prevention of strictures after duodenal endoscopic submucosal dissection (with video). ... Differential diagnosis of superficial duodenal epithelial tumor and non-neoplastic lesion in duodenum by magnified endoscopic ... Intensive endoscopic resection strategy for multiple duodenal polyposis associated with familial adenomatous polyposis. Iwata, ...
NeoplasmDuodenal NeoplasmsTesticular NeoplasmsNeoplasms, Muscle TissuePleural NeoplasmsCystadenocarcinoma, MucinousGallbladder ... Pancreatic NeoplasmsNeoplasmsLymphatic MetastasisSkin NeoplasmsNeoplasms, Cystic, Mucinous, and SerousLung NeoplasmsNeoplasms, ... Cord NeoplasmsVaginal NeoplasmsAdrenal Gland NeoplasmsNervous System NeoplasmsPenile NeoplasmsNeoplasm SeedingGenital Neoplasms ... Uterine NeoplasmsBreast NeoplasmsColonic NeoplasmsBone Marrow NeoplasmsEndocrine Gland NeoplasmsIntestinal NeoplasmsNeoplasms, ...
Neoplasms 69% * Pancreatic Neoplasms 68% * Duodenal Neoplasms 56% * Bile Duct Neoplasms 51% ...
small intestine neoplasm DOID:7505 * chronic duodenal ileus DOID:13687 * anal gland adenocarcinoma ...
Neuroendocrine Neoplasms are considered solid tumours.Imugene Limited, a clinical-stage immuno-oncology company, and City of ... A spotlight on duodenal Neuroendocrine Neoplasms (dNENs). *A spotlight on Rectal Neuroendocrine Neoplasms ... Neuroendocrine Neoplasms are considered solid tumours.. Imugene Limited, a clinical-stage immuno-oncology company, and City of ... The ENETS 2023 guideline for gNETs are combined with the guidelines for Duodenal NET (dNET) due to their close relationship in ...
duodenal benign neoplasm DOID:1737 * perineurioma DOID:4697 * gastroesophageal junction adenocarcinoma DOID:4944 ...
Duodenal Neoplasms Medicine & Life Sciences 20% * Acids Medicine & Life Sciences 19% * Protein Structure Chemical Compounds 18% ... Helicobacter pylori is a widespread human bacterial pathogen responsible for inducing gastric and duodenal ulcers and gastric ... N2 - Helicobacter pylori is a widespread human bacterial pathogen responsible for inducing gastric and duodenal ulcers and ... AB - Helicobacter pylori is a widespread human bacterial pathogen responsible for inducing gastric and duodenal ulcers and ...
A spotlight on duodenal Neuroendocrine Neoplasms (dNENs). *A spotlight on Rectal Neuroendocrine Neoplasms ... Neuroendocrine Neoplasms are not so special in this regard). Almost all will say they dont need reminding that it might be an ... Anyone who says that the group of diseases called Neuroendocrine Neoplasms (the correct scientific term) is rare, is clearly ...
... deletion valorant scripts free trial the god mode script payday 2 gene in duodenal gastrin and somatostatin cell neoplasms and ...
Tubulovillous adenomas of the duodenal ampulla are rare neoplasms. The present report describes a case with radiological- ... SUMMARY Tubulovillous adenomas of the duodenal ampulla are rare neoplasms. The present report describes a case with ... Hepatocellular carcinoma (HCC) is the most common primary neoplasm of the liver, mainly secondary to cirrhosis caused by ... RESUMO Os adenomas túbulo-vilosos da ampola duodenal são neoplasias raras. Neste trabalho apresentamos um caso com correlação ...
Neoplasms of the stomach, duodenal, pancreas, and biliary tract. *Treat stomach ulcers ...
Duodenal Gastric Metaplasia and Duodenal Neuroendocrine Neoplasms: More Than a Simple Coincidence? 01 - Articolo su rivista ... Duodenal Gastric Metaplasia and Duodenal Neuroendocrine Neoplasms: More Than a Simple Coincidence?. ... Risk of preoperative understaging of duodenal neuroendocrine neoplasms: a plea for caution in the treatment strategy. ... Risk of preoperative understaging of duodenal neuroendocrine neoplasms: a plea for caution in the treatment strategy 01 - ...
  • Papillary tumors are unusual entities, making up less than 5% of all new digestive tract neoplasms in the United States. (medscape.com)
  • Periampullary cancers can be broadly considered as tumors arising within 1 cm of the ampulla of Vater and include ampullary, distal bile duct, pancreatic, and duodenal cancers. (medscape.com)
  • Although malignant tumors of the main papilla are more common, a number of benign neoplasms also may arise in the periampullary area, including benign adenomas (tubular and villous), lipomas, hamartomas, fibromas, and neurogenic tumors. (medscape.com)
  • Duodenal carcinoids have morphologic and functional similarities to pancreatic islet-cell tumors. (medscape.com)
  • Duodenal neuroendocrine neoplasms (dNENs) are heterogeneous tumors that can exhibit aggressive behavior, with loco-regional nodes and distant metastases. (enets.org)
  • Sporadic tumors of the duodenal papilla are rare, with a prevalence of 0.04% to 0.12% in autopsies [1], most of which are adenomas histologically [2].They can arise from epithelium or the inner lining of the ampulla. (biomedres.us)
  • The combination of duodenal GIST and gastrointestinal bleeding consist of a rare presentation for such tumors. (scielo.org)
  • Intraductal papillary mucinous neoplasm of the ileal heterotopic pancreas in a patient with hereditary non-polyposis colorectal cancer: A case report. (wjgnet.com)
  • In 1946, Waugh and Clagett described a formal en-bloc resection of the gallbladder with the common bile duct (CBD), gastric antrum, duodenum, and head of pancreas performed as a one-stage procedure, which we recognize today as the classic pancreaticoduodenectomy. (medscape.com)
  • The head of the pancreas lies in the duodenal C loop in front of the inferior vena cava (IVC) and the left renal vein (see the images below). (medscape.com)
  • Pancreatic cystic neoplasms (PCNs) are predominantly benign entities which represent almost 50 percent of all cystic lesions of the pancreas. (ijsurgery.com)
  • Mucinous cystic neoplasm of the pancreas presenting with hemosuccus pancreaticus: Report of a case. (ijsurgery.com)
  • Hemosuccus pancreaticus caused by a mucinous cystic neoplasm of the pancreas. (ijsurgery.com)
  • Serous cystic neoplasm of the pancreas: a multinational study of 2622 patients under the auspices of the Internstional Association of Pancreatology and European Pancreatic Club (European Study Group on Cystic Tumours of the Pancreas). (ijsurgery.com)
  • Risk of malignancy in serous cystic neoplasms of the pancreas. (ijsurgery.com)
  • Resected serous cystic neoplasms of the pancreas: a review of 158 patients with recommendations for treatment. (ijsurgery.com)
  • Tseng JF, Warshaw AL, Sahani DV, Lauwers GY, Rattner DW, Fernandez-del Castillo C. Serous cystic neoplasms of the pancreas: tumour growth rates and recommendations for treatment. (ijsurgery.com)
  • Das A, Wells C, Nguyen CC. Incidental cystic neoplasms of the pancreas: what is the optimal interval of imaging surveillance. (ijsurgery.com)
  • The patient's duodenal obstruction had been caused by metastatic urothelial carcinoma within the pancreas. (hcahealthcare.com)
  • This is the first description of a patient presenting with duodenal obstruction caused by urothelial carcinoma metastasizing to the pancreas. (hcahealthcare.com)
  • Tubular adenoma wase the most common type (63.6%) of non-ampullary duodenal neoplasms. (archive.org)
  • Preoperative endoscopic diagnosis and timely treatment are important for the clinical management of sporadically superficial nonampullary duodenal epithelial tumours (SNADETs), including adenoma and adenocarcinoma limited to the submucosal layer. (biomedcentral.com)
  • Superficial nonampullary duodenal epithelial tumours (SNADETs), including adenoma and adenocarcinoma limited to the submucosal layer, are rare, but the treatment outcomes for advanced cases are not satisfactory [ 1 ]. (biomedcentral.com)
  • Low-grade duodenal adenoma (LGA) can be followed up, but high-grade adenoma (HGA) or higher among SNADETs without metastasis should be treated by endoscopic resection, including endoscopic mucosal resection (EMR) and endoscopic submucosal dissection (ESD). (biomedcentral.com)
  • adenoma, dysplasia) lesion on the esophageal, gastric, duodenal or colorectal mucosa - non-epithelial (eg. (who.int)
  • According to multiple modalities and lab examination, we made a definite diagnosis of duodenal neoplasm. (biomedres.us)
  • Immunohistochemical staining of the resected specimen confirmed the diagnosis of duodenal GIST with colon wall invasion. (scielo.org)
  • Malignant Duodenal Obstruction Caused by Urothelial Carcinoma" by Dylan Johnson, Ankita Mishra et al. (hcahealthcare.com)
  • Endoscopic ultrasonography was then performed, showing a hypoechoic mass at the major duodenal papilla continuing to the lower common bile duct. (biomedres.us)
  • A direct symptom of major duodenal papilla tumor is revealing of a space-occupying process in its projection. (bioplasm-nls.com)
  • Fibrogastroduodenoscopy and three-dimensional Bioplasm machine have a significant importance in diagnostics of major duodenal papilla tumo. (bioplasm-nls.com)
  • Aneurysmal dilatation of the lumen may be seen and excludes other more common causes of duodenal wall neoplastic infiltration, namely adenocarcinoma. (eurorad.org)
  • Endoscopic and surgical management of nonampullary duodenal neoplasms. (msdmanuals.com)
  • Endoscopic resection of duodenal neoplasms is widely used recently and it is an alternative treatment strategy to surgical excision. (archive.org)
  • This study aimed to evaluate the safety and efficacy of endoscopic resection of duodenal neoplasms and to determine its outcomes. (archive.org)
  • Conclusions: Endoscopic resection of duodenal neoplasm is a safe and effective treatment modality that can replace surgical resection in many cases. (archive.org)
  • EMR frequently leads to a piecemeal resection, while ESD ensures a high en bloc resection rate with a high risk of complications. (biomedcentral.com)
  • Laparoscopic endoscopic cooperative surgery is a promising treatment for SNADETs with excellent rates of en bloc resection and a low risk of complications, although it is expensive and requires many specialists. (biomedcentral.com)
  • En-bloc resection of the tumor was carried out, included the fourth portion of the duodenum and the transverse and descending colon, without postoperative complications. (scielo.org)
  • A case of duodenal hemorrhage due to arteriorvenous malformation around a serous cystic neoplasm. (ijsurgery.com)
  • Incidental pancreatic cystic neoplasms in an asymptomatic healthy population. (ijsurgery.com)
  • European evidence-based guidelines on pancreatic cystic neoplasms. (ijsurgery.com)
  • Tumour size and location correlate with behavior is pancreatic serous cystic neoplasms. (ijsurgery.com)
  • He had performed the procedure on three patients as a two-stage operation for periampullary neoplasms, then later refined his methodology to a one-stage procedure. (medscape.com)
  • Duodenal NENs (D-NENs) are increasing in incidence often incidentally identified at endoscopy. (enets.org)
  • A 73-year-old man was admitted into our hospital with the chief complaint that neoplasm of the duodenal papilla was discovered under screening endoscopy for four months. (biomedres.us)
  • APC:T1556fs and STK11 mutations in duodenal adenomas and adenocarcinomas. (cdc.gov)
  • Sporadic adenomas of the duodenal papilla are rare to screen in clinical practice that may become potentially invasive if left untreated. (biomedres.us)
  • The benign adenomas of duodenal papilla are endoscopically feasible, and it offers a treatment procedure. (biomedres.us)
  • A 73-year-old man was admitted to our hospital for diagnosis and treatment for duodenal adenomas. (biomedres.us)
  • Villous or tubulovillous adenomas of the ampulla of Vater are particularly interesting since they may harbor an undetected malignant neoplasm that could become invasive if left untreated. (biomedres.us)
  • The enlarging experience with removing colorectal polyps with snare polypectomy led to the recognition that the benign adenomas of duodenal papilla are endoscopically feasible [3]. (biomedres.us)
  • INTRODUÇÃO: O tumor estromal gastrointestinal (GIST) é neoplasia pouco freqüente, sendo rara a combinação de acometimento duodenal e hemorragia digestiva, por isso apresenta-se este relato. (scielo.org)
  • Encontrado na laparotomia de urgência tumor em quarta porção duodenal com invasão de cólon em ângulo esplênico, sendo realizada ressecção em bloco do duodeno acometido, segmento de cólon transverso e descendente, com boa evolução pós-operatória. (scielo.org)
  • BACKGROUND: Gastrointestinal stromal tumor (GIST) represents an uncommon form of neoplasm. (scielo.org)
  • Administration of chenodeoxycholate in the diet increased duodenal tumor number in Min/+ mice. (houstonmethodist.org)
  • Promotion of duodenal tumor formation was accompanied by increased β-catenin expression in duodenal cells, as well as increased PGE 2 in duodenal tissue. (houstonmethodist.org)
  • Background/Aims: Sporadic non-ampullary duodenal neoplasms are rare and optimal treatment for these lesions remains undefined. (archive.org)
  • Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms . (lookformedical.com)
  • Duodenal malignancies presenting with jaundice due to extrahepatic biliary obstruction occur in 43% of cases, but the exact prevalence of obstructive jaundice in duodenal lymphoma is unknown, although there are a few cases reported [5]. (eurorad.org)
  • The CT appearance of duodenal lymphoma is variable: aneurysmal, constrictive, nodular and ulcerative infiltration. (eurorad.org)
  • Abstract: Lymphoma is the most common malignant hematopoietic neoplasm in domestic felines. (visavet.es)
  • Twenty-two cases of feline epitheliotropic duodenal T-cell lymphoma were characterized morphologically and immunohistochemically (CD3, Pax5, Ki-67), and Bcl-2 immunoexpression was established. (visavet.es)
  • Duodenal/Pyloric Stent is indicated for use in the palliative treatment of gastroduodenal obstruction caused by malignant neoplasms. (medorah.com)
  • Neuroendocrine Neoplasms are considered solid tumours. (ronnyallan.net)
  • Therefore, it is feasible to resect and cure duodenal tumours at the precancerous stage with less invasive endoscopic treatment under early endoscopic diagnosis. (biomedcentral.com)
  • However, preoperative biopsy is undesirable for duodenal tumours, since it has poor accuracy and may cause unexpected submucosal fibrosis. (biomedcentral.com)
  • Although innumerable details of pancreaticoduodenectomy yield to continued innovation, a comprehensive discussion of intraoperative variants (ie, duct to mucosa vs invagination of the pancreaticojejunal anastomosis, diverse approaches to vein reconstructions, nuances of each enteric anastomosis, and modifications of Roux-en-Y reconstructions, to name a few) is beyond the scope of this article. (medscape.com)
  • Eighteen (54.5%) lesions were found in the second portion of the duodenum, and 10 (30.3%) lesions on bulb and 3 (9.1%) lesions on superior duodenal angle. (archive.org)
  • Methods: We included 35 gastric cancer patients and 31 duodenal ulcer patients, which are considered the variant outcomes. (unair.ac.id)
  • Helicobacter pylori is a widespread human bacterial pathogen responsible for inducing gastric and duodenal ulcers and gastric cancers. (wustl.edu)
  • The second neoplasm may have the same or different histological type and can occur in the same or different organs as the previous neoplasm but in all cases arises from an independent oncogenic event. (lookformedical.com)
  • Transfer of a neoplasm from its primary site to lymph nodes or to distant parts of the body by way of the lymphatic system. (lookformedical.com)
  • Duodenal/Pyloric stent features 12 radiopaque platinum markers enabling fluoroscopic visualization of the stent. (medorah.com)
  • In this study, we examined the phylogenetic origins of strains from gastric cancer and duodenal ulcer patients living in Bogota, Colombia. (unair.ac.id)
  • thus, we did not detect any difference in phylogenetic distribution between gastric cancer and duodenal ulcer strains in the hpEurope group in Colombia. (unair.ac.id)
  • Conclusions: Our study showed that a phylogeographic origin determined by MLST was insufficient for distinguishing between gastric cancer and duodenal ulcer risk among hpEurope strains in the Andean region in Colombia. (unair.ac.id)
  • This duodenal thickening caused biliary and pancreatic ducts dilatation. (eurorad.org)
  • Bypass surgery is done in some cases to relieve the biliary and duodenal obstruction [4]. (eurorad.org)
  • Physiological pancreatico-duodenal DOTA-Exendin-4 uptake in the Brunner's glands of the proximal duodenum occurs in Glucagon-like peptide-1 receptor (GLP-1R) imaging and is a known potential pitfall. (enets.org)